The United States Food and Drug Administration (FDA) has approved Israel-based Oramed Pharmaceuticals Inc's (NASDAQ :ORMP)(TASE: ORMP) Investigational New Drug application (IND) for human trials of its oral GLP-1 analogue capsule ORMD-0901, it was reported yesterday.
The product is utilised in the treatment of type 2 diabetes and presently only offered through injection. In a prior Phase one study on type two diabetic patients, the company's ORMD-0901 capsule was well tolerated and indicated encouraging efficacy, including decreasing blood sugar levels following a standard meal as compared to a placebo.
The company's planned Phase one pharmacokinetic study is a fully-randomised, single-blind, placebo-controlled four-way crossover study that will assess safety in addition to the pharmacokinetics of ORMD-0901 compared to placebo and to open label Byetta, a GLP-1 analogue presently on the market, in up to 15 healthy subjects.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults